ATE280496T1 - Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin - Google Patents

Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin

Info

Publication number
ATE280496T1
ATE280496T1 AT97934183T AT97934183T ATE280496T1 AT E280496 T1 ATE280496 T1 AT E280496T1 AT 97934183 T AT97934183 T AT 97934183T AT 97934183 T AT97934183 T AT 97934183T AT E280496 T1 ATE280496 T1 AT E280496T1
Authority
AT
Austria
Prior art keywords
heparin
desulfatized
treating asthma
reducing
response
Prior art date
Application number
AT97934183T
Other languages
English (en)
Inventor
Thomas P Kennedy
Original Assignee
Paringenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paringenix Inc filed Critical Paringenix Inc
Application granted granted Critical
Publication of ATE280496T1 publication Critical patent/ATE280496T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT97934183T 1996-07-29 1997-07-03 Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin ATE280496T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2439196P 1996-07-29 1996-07-29
PCT/US1997/012419 WO1998004133A1 (en) 1996-07-29 1997-07-03 Methods of treating asthma with o-desulfated heparin

Publications (1)

Publication Number Publication Date
ATE280496T1 true ATE280496T1 (de) 2004-11-15

Family

ID=21820348

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934183T ATE280496T1 (de) 1996-07-29 1997-07-03 Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin

Country Status (9)

Country Link
US (1) US5990097A (de)
EP (1) EP0918461B1 (de)
JP (1) JP4097044B2 (de)
AT (1) ATE280496T1 (de)
AU (1) AU727352B2 (de)
CA (1) CA2261872C (de)
DE (1) DE69731386T2 (de)
ES (1) ES2231880T3 (de)
WO (1) WO1998004133A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001278A1 (en) * 1994-07-01 1996-01-18 Seikagaku Corporation Process for producing desulfated polysaccharide, and desulfated heparin
BR9806540C1 (pt) * 1998-06-09 2001-05-08 Akira Yoshitome Produto farmacêutico para tratamento de hemofilia e de bronquite asmática
CZ2001584A3 (cs) * 1998-08-18 2002-06-12 The Regents Of The University Of California Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
EP1109919A2 (de) 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Von heparinase i und ii abgeleitete heparinasen
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
WO2000065521A2 (en) 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
AU2001243512C1 (en) * 2000-03-08 2008-04-17 Massachusetts Institute Of Technology Heparinase III and uses thereof
EP1328260A2 (de) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Verfahren und produkte zur pulmonalen verabreichung von polysacchariden
CA2483271A1 (en) * 2002-04-25 2003-11-06 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
AU2002952559A0 (en) * 2002-11-08 2002-11-21 Fujisawa Pharmaceutical Co., Ltd. New use
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
US20080207489A1 (en) * 2007-02-21 2008-08-28 John Castellot Use of CCN5 for treatment of smooth muscle proliferation disorders
US20090054374A1 (en) * 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
EP2205642B1 (de) * 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Nicht gerinnungshemmende polysaccharidzusammensetzungen
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20120302909A1 (en) * 2009-11-11 2012-11-29 Mayse Martin L Methods and systems for screening subjects
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
WO2011159770A2 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
TW201306847A (zh) * 2010-11-30 2013-02-16 Vectura Ltd 組成物及用途
KR102165348B1 (ko) 2012-05-09 2020-10-14 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
WO2014193818A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380716A (en) * 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
AU3938093A (en) * 1992-04-02 1993-11-08 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby

Also Published As

Publication number Publication date
AU727352B2 (en) 2000-12-14
EP0918461A1 (de) 1999-06-02
JP4097044B2 (ja) 2008-06-04
WO1998004133A1 (en) 1998-02-05
CA2261872A1 (en) 1998-02-05
CA2261872C (en) 2004-06-15
JP2001506673A (ja) 2001-05-22
EP0918461A4 (de) 2002-11-13
EP0918461B1 (de) 2004-10-27
DE69731386T2 (de) 2006-02-16
DE69731386D1 (de) 2004-12-02
US5990097A (en) 1999-11-23
AU3729997A (en) 1998-02-20
ES2231880T3 (es) 2005-05-16

Similar Documents

Publication Publication Date Title
ATE280496T1 (de) Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin
DE69518729D1 (de) Stickstoffoxyd abgebendes präparat zur behandlung von analen erkrankungen
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
DE69033626D1 (de) Mittel zur Hemmung des Komplementsystems hergestellt aus Fucanen aus braunen Algen
DE59505211D1 (de) Beatmungsgerät, insbesondere zur behandlung von ateminsuffizienzen, sowie verfahren zu dessen betrieb
SE9404196D0 (sv) New antithrombotic formulation
DE3782917D1 (de) Verfahren zum herabsetzen des gehalts an rueckstaendigen aldehyden in implantierbaren bioprosthetischen geweben.
SE9002522L (sv) Metod foer framstaellning av en farmaceutisk komposition i form av mikropartiklar
DE59210000D1 (de) Verfahren zur Herstellung einer stabilen Fibrinogenlösung
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
YU45295A (sh) Supstituisani benzamidini, njihovo pripremanje i primena kao lekova
FI972703L (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
AU4626389A (en) Use of minoxidil for wound healing
ATE210149T1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
IL139616A0 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
ATE162218T1 (de) Verfahren zur herstellung eines virussicheren thrombinkonzentrates
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
BR0107544A (pt) Composição de promoção de secreção de bile
AT389065B (de) Verfahren zur herstellung eines brenners, insbesondere gasbrenners sowie nach diesem verfahren hergestellter brenner
JPS5569595A (en) Novel substance having fibrinolytic activity, remedy for thrombotic embolic disease comprising it, and its preparation
EA199800819A1 (ru) Способ лечения биполярного расстройства
ATE110961T1 (de) Behandlung von beatmungsabhängigkeit mit wachstumshormon.
张云翔 et al. Taphonomic characteristics of Longjiagou Hipparion Fauna and genesis of'Hipparion red clay'in Wudu County, Gansu Province

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties